Better Health for All

Immunome, Inc. is entirely focused on developing first-in-class and best-in-class targeted cancer therapies, with a pipeline including varegacestat in Phase 3, IM-1021 in Phase 1, and IM-3050 with an IND submitted in March 2025, along with preclinical candidates.

This indicates that 100% of its product portfolio is dedicated to providing substantial health benefits, and it has no products with negative health impacts. The company reported $129.5 million in research and development expenses for the year ended December 31, 2024, and $152.3 million in in-process R&D expenses for the same period, demonstrating significant investment in health innovation. The company's Code of Business Conduct and Ethics, effective since 2020 and posted on its website, outlines a commitment to ethical research procedures, proper scientific conduct, and compliance with laws, including those related to environmental impact and handling of personally identifiable information. It also provides a compliance hotline and external website for reporting violations. However, the code also states that violations may result in disciplinary action, including termination, civil legal action, or criminal prosecution, and mentions severe penalties for antitrust violations, indicating potential risks. The company executes clinical trials, with specific trials mentioned for varegacestat and IM-1021, and an IND submitted for IM-3050, but no specific ethical frameworks or diversity practices are detailed beyond a general commitment to ethical research procedures.

Honest & Fair Business

Immunome, Inc. has a formal whistleblower policy with a confidential and anonymous toll-free hotline and an email address, allowing for anonymity.

This hotline is required by the SEC for complaints regarding accounting, internal accounting controls, or auditing matters, with messages delivered directly to the Audit Committee. However, there is no evidence of independent investigation processes, training frequency, or resolution times. The company also has a separate Anti-Corruption Policy that references the Foreign Corrupt Practices Act (FCPA) and other anti-corruption laws, but there is no information on its enforcement, training frequency, or effectiveness metrics.

Kind to Animals

Immunome, Inc. conducts preclinical research involving animal testing to assess product safety and for studies on immune responsiveness and tumor growth using mouse models.

There is no publicly available information regarding a formal animal testing policy, specific reduction targets, or the number of animals used annually. The company's continued reliance on animal testing for preclinical studies, without any disclosed policy for reduction or alternatives, indicates a lack of commitment to minimizing animal use.

No War, No Weapons

Immunome, Inc. is a biopharmaceutical company focused on developing therapeutics. The company received a contract from the US Department of Defense for COVID-19 antibody development, which was increased to $17.6 million.

However, this contract is explicitly stated to be for a specific medical countermeasure and not for arms or defense contracts.

Safe & Smart Tech

The company provides users with comprehensive data control rights, including the ability to opt-out of marketing, access, correct, delete, transfer, restrict processing, object to processing, and withdraw consent for their personal information.

It also practices data minimization by explicitly asking users not to provide health-related information through its digital properties. Furthermore, the company states its compliance with applicable laws, including the GDPR for European users and the UK GDPR.